Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Leases (2019 - 2023)

Spyre Therapeutics' Current Leases history spans 5 years, with the latest figure at $4.3 million for Q2 2023.

  • For Q2 2023, Current Leases rose 807.97% year-over-year to $4.3 million; the TTM value through Jun 2023 reached $4.3 million, up 807.97%, while the annual FY2022 figure was $625000.0, 43.35% up from the prior year.
  • Current Leases reached $4.3 million in Q2 2023 per SYRE's latest filing, up from $608000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.3 million in Q2 2023 to a low of $228000.0 in Q2 2020.
  • Average Current Leases over 5 years is $618277.8, with a median of $381500.0 recorded in 2019.
  • Peak YoY movement for Current Leases: plummeted 30.49% in 2020, then soared 807.97% in 2023.
  • A 5-year view of Current Leases shows it stood at $351000.0 in 2019, then decreased by 9.12% to $319000.0 in 2020, then surged by 36.68% to $436000.0 in 2021, then soared by 43.35% to $625000.0 in 2022, then surged by 592.96% to $4.3 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Current Leases are $4.3 million (Q2 2023), $608000.0 (Q1 2023), and $625000.0 (Q4 2022).